Legend Biotech Corp

NASDAQ:LEGNUnited States

Nov 12, 2024

Show headlines and story abstract

• Legend Biotech Q3 Loss Widens, Revenue Rises, from 7:45AM ET on Tuesday Nov 12, 2024 by MT Newswires

  7:45AM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: LEGN
  07:45 AM EST, 11/12/2024 (MT Newswires) -- Legend Biotech (LEGN) reported Q3 loss Tuesday of $0.34 per diluted share, wider than the loss of $0.17 a year earlier. Two analysts surveyed by Capital IQ expected a loss of $0.58. Revenue for the quarter ...

• Stocks Down Pre-Bell After Record Highs as Earnings Season Wanes; Asia, Europe Fall, from 7:01AM ET on Tuesday Nov 12, 2024 by MT Newswires

  7:01AM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: HD, MOS, OXY, FLUT, TSN, SE, SPOT, TME, AZN, LEGN, ROIV, ONON, IGT, SHOP, SATS
  07:01 AM EST, 11/12/2024 (MT Newswires) -- US equity markets were trending downward before the open Tuesday after closing at record highs a day earlier as traders assess the waning earnings season. Standard & Poor's 500 futures declined 0.2% in prem...

• Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

  7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: LEGN
  
  Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
  -- CARVYKTI(R) (ciltacabtagene autoleucel; cilta-cel) updates: -- Net trade sales of approximately $286 million, representing operational growth of 87.6% year-over-year and 53.2% quarter-over-quarter -- First and only cell therapy clinically shown to significantly extend overall survival versus standard therapies in multiple myeloma patients as early as second line; presented CARTITUDE-4 three-year follow-up data at the International Myeloma Society Annual Meeting -- Initiated commercial production at Obelisc facility in Ghent, Belgium -- Launched in Switzerland during the third quarter and recently received label expansion into third-line plus settings for multiple myeloma patients -- Received China's NMPA approval for the treatment of fourth-line plus multiple myeloma -- Recently appointed Alan Bash as President of CARVYKTI(R) -- Announced plans for new, state-of-the-art cell therapy R&D facility in Philadelphia -- Cash and cash equivalents, and time deposits of $1.2 billion, as of September 30, 2024, which Legend Biotech believes will provide financial runway into 2026, when Legend Biotech anticipates achieving an operating profit
  

• *DJ Legend Biotech 3Q Rev $160.2M >LEGN, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

  7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: LEGN